All In Biotech

Drug Trial Radar · NCT03943589

A Study of Imlifidase in Patients With Guillain-Barré Syndrome

An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients

Last checked: Nov 19, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Nov 12, 2019

Primary completion

Feb 27, 2024

Study completion Feb 27, 2024

Sponsor

Lead sponsor
Hansa Biopharma ABIndustry
Sponsor type
Industry
First posted
May 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study participants are patients which have been diagnosed with Guillain-Barré Syndrome (GBS) and are planned to receive treatment with intravenous immunoglobulin (IVIg). IVIg is a standard of care treatment for GBS patients. The patients in this study will be treated with the study medicine imlifidase on day 1, and with IVIg on days 3-7. The purpose of this study is to investigate the safety and effectiveness of imlifidase in patients diagnosed with GBS.

Conditions

  • Guillain-Barré Syndrome (GBS)

Interventions

  • ImlifidaseDrug

    All subjects will receive imlifidase (Day 1) prior to standard care IVIg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Guillain Barré Syndrome Disability Score (GBS DS) - Time to Improve by at Least 1 GradeTime frame: Baseline to Day 360
  2. Guillain Barré Syndrome Disability Score (GBS DS) - Time to Improve by at Least 2 GradesTime frame: Baseline to Day 360
  3. Guillain Barré Syndrome Disability Score (GBS DS) - Ability to Walk UnaidedTime frame: Baseline to Day 360
  4. Proportion of Patients Who Are Able to Run Over Time (GBS DS≤1)Time frame: Baseline to Day 360
  5. Mean MRC Sum Score Over TimeTime frame: Baseline until Day 180
  6. Change From Baseline in MRC Sum Score Over TimeTime frame: Baseline until Day 180
  7. Mean R-ODS Over TimeTime frame: Baseline to Day 360
  8. Change From Baseline in R-ODS Over TimeTime frame: Baseline to Day 360
  9. Days in HospitalTime frame: Baseline to Day 360
  10. Time in an ICUTime frame: Baseline until Day 360
  11. Need for Mechanical VentilationTime frame: Baseline until Day 180
  12. Patient's Health State Over Time as Assessed by EQ VASTime frame: Day 8, Day 15, Day 29, Day 57, Day 92, Day 180, and Day 360

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • CHU Bordeaux - Hôpital Pellegrin Tripode

    Bordeaux, France

  • CHU de Limoges - Hôpital Dupuytren

    Limoges, France

  • Hôpital de la Timone - Centre de référence des maladies neuromusculaires et de la SLA

    Marseille, France

  • CHU de Montpellier, Hôpital Gui de Chauliac

    Montpellier, France

  • Centre Hospitalier Universitaire de Nantes

    Nantes, France

  • Service de neurologie, Hôpitaux Universitaires de Strasbourg

    Strasbourg, France

  • CHU Le Kremlin-Bicêtre. Service Neurologie

    Le Kremlin-Bicêtre, Paris, France

  • Amsterdam UMC

    Amsterdam, Netherlands

  • Erasmus Medical Centre

    Rotterdam, Netherlands

  • Queen Elizabeth University Hospital Glasgow

    Glasgow, United Kingdom

  • Oxford University Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.